Nature Communications (Jun 2020)

Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer

  • Wuqing Huang,
  • Jan Sundquist,
  • Kristina Sundquist,
  • Jianguang Ji

DOI
https://doi.org/10.1038/s41467-020-17028-4
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 9

Abstract

Read online

Phosphodiesterase-5 (PDE5) inhibitors have been suggested to have an anti-tumor effect and block surgery-induced immunosuppression. Here, the authors show that postdiagnostic use of PDE5 inhibitors is associated with a decreased risk of colorectal cancerspecific mortality as well as a decreased risk of metastasis.